New insight on how a parasite can resist current therapies has been published today in the open-access eLife journal.
The study in cultures of human cells infected with Trypanosoma cruzi (T. cruzi), the parasite that causes Chagas disease, suggests that its metabolic state influences the effectiveness of azole drugs that inhibit its growth. These findings could be useful for the development of more effective antimicrobial treatments.
Chagas disease, also known as American trypanosomiasis, can cause a sudden, brief (acute) illness, or it may be a long-lasting (chronic) condition. Around six to seven million people worldwide are estimated to be infected with the T. cruzi pathogen that causes the disease, according to the World Health Organization. Symptoms can range from mild to severe, but do not often appear until the chronic stage of disease.
“The goal for the treatment of Chagas and other infectious diseases is to eliminate the pathogen